Literature DB >> 21867931

1990-2010: two decades of interferon-based therapy.

Maria Buti1, Rafael Esteban.   

Abstract

Twenty-five years have passed since interferon-α was first used in the treatment of chronic hepatitis C infection, and even now it remains an essential part of the standard of care for this condition. At present, the recommended treatment is a combination of pegylated interferon and ribavirin A. There have been enormous advances in our understanding of the mechanisms through which interferon works and in identifying factors related to the response to this treatment. Even with the development of new protease inhibitors, it is likely that interferon will remain an essential component of hepatitis C treatment.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21867931     DOI: 10.1016/j.cld.2011.05.007

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  3 in total

1.  Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay.

Authors:  Zongyi Hu; Xin Hu; Shanshan He; Hyung Joon Yim; Jingbo Xiao; Manju Swaroop; Cordelle Tanega; Ya-qin Zhang; Guanghui Yi; C Cheng Kao; Juan Marugan; Marc Ferrer; Wei Zheng; Noel Southall; T Jake Liang
Journal:  Antiviral Res       Date:  2015-10-26       Impact factor: 5.970

2.  Potent inhibition of Hendra virus infection via RNA interference and poly I:C immune activation.

Authors:  Jana L McCaskill; Glenn A Marsh; Paul Monaghan; Lin-Fa Wang; Timothy Doran; Nigel A J McMillan
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

3.  Replication priority of hepatitis C virus genotype 2a in a Chinese cohort.

Authors:  Zhen Yang; Yongxin Yu; Hongzhong Zhang; Guifang Shang; Jialiang Gao; Jian-Dong Jiang; Zonggen Peng
Journal:  Acta Pharm Sin B       Date:  2014-07-14       Impact factor: 11.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.